| Cas No.: | 1421373-66-1 |
| 名称: | |
| 别名: | Mereletinib mesylate; EGFR inhibitor; AZD9291 mesylate; AZD 9291 mesylate，Tagrisso |
| SMILES: | C(NC1=CC(NC2=NC=CC(C3C4=C(N(C)C=3)C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C)(=O)C=C.CS(O)(=O)=O |
| 分子式: | C29H37N7O5S |
| 分子量: | 595.71 |
| 纯度: | |
| 保存条件: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | |
| In Vivo: | |
| In Vitro: | |
| References: | AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM). IC50 value: 12.92 nM(Exon 19 deletion EGFR); 11.44 nM(L858R/T790M EGFR) Target: L858R/T790M EGFR; Exon 19 deletion EGFR AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines. |
| Kinase Assay: | |
| Cell Assay: | |
| Animal Administration: | |
| References: |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
